BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (AMEX: AKN) and Strides Arcolab Limited (NSE: STAR, BSE: 532531) today announced that both Companies have agreed to fund, develop, and commercialize an additional 10 ANDA injectable drug products for the Akorn-Strides, LLC Joint Venture. Akorn and Strides created and funded the Joint Venture in 2005 and since that time have developed and submitted 15 ANDA’s. Prior to year end, the Joint Venture expects to submit an additional 2 ANDA’s for a total of 17 ANDA’s filed in 2006. The Joint Venture is developing liquid, lyophilized and dry powder fill generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
